NuVasive (NUVA) Cash Flow Statement

Click line-items for a historical chart and %

Consolidated net income	29.46M
Depreciation and amortization
Stock-based compensation	19.65M
Allowance for excess and obsolete inventory
Allowance for doubtful accounts and sales return reserves, net of write-offs
Accretion of contingent consideration
Other non-cash adjustments	11.37M
Accounts receivable	-3.04M
Inventory	-22.42M
Prepaid expenses and other current assets	-3.46M
Accounts payable and accrued liabilities	5.94M
Accrued payroll and related expenses	-1.67M
Income taxes payable
Net cash provided by operating activities
Purchases of property and equipment	-73.88M
Purchases of marketable securities	-128.96M
Sales of marketable securities	407.03M
Purchases of restricted investments
Payment for specific rights in connection with supply agreement, net of refund received	-5.92M
Net cash provided by (used in) investing activities
Proceeds from the sale of warrants	44.85M
Proceeds from the issuance of convertible debt, net of issuance costs	634.14M
Purchase of convertible note hedges
Proceeds from the issuance of common stock	6.67M
Other assets	-1.7M
Tax benefits related to stock-based compensation awards	0
Net cash provided by financing activities
Effect of exchange rate changes on cash
Increase in cash and cash equivalents	11.48M
Cash and cash equivalents at beginning of period	192.34M
Cash and cash equivalents at end of period	203.82M

Entities mentioned with NUVA

View All Entities